AURYXIA has a proven safety profile

Explore the safety and tolerability profile for AURYXIA to see if it is right for your adult patients.1

A pooled safety analysis that included a 52-week pivotal study1

The most common adverse reactions reported with AURYXIA were1:

Adverse reactions in >5% of patientsAURYXIA
Discolored feces19%

In a pooled safety analysis of the 52-week pivotal study and 3 short-term trials (N=557), the majority of diarrhea cases (56%) resolved within 2 weeks from onset1-3

Safety and tolerability profile evaluated in a 52-week trial1

41.9% of patients on AURYXIA experienced an SAE compared to 49.7% on Active Control5

No individual SAEs were observed in more than 5% of patients treated with AURYXIA

SAEs occurring in ≥10% of patients taking AURYXIA vs Active Control by system organ class3,5AURYXIA
Gastrointestinal disorders7.6%12.8%
Cardiac disorders7.6%11.4%
Infection and infestations13.8%19.5%

SAE=serious adverse event; Active Control=sevelamer carbonate and/or calcium acetate.

See how AURYXIA helped patients reach their target goals

AURYXIA helped patients reach and stay in the range of 3.5-5.5 mg/dL during a 56-week trial.1
Patients had a mean serum phosphorus level of 7.41 mg/dL at baseline and 4.88 mg/dL at Week 56.6


See trial design

You may also be interested in: 


Trial design1,8

A multicenter, randomized, open‐label trial evaluated the ability of AURYXIA to lower serum phosphorus in patients with CKD on dialysis over 56 weeks. Eligible patients had serum ferritin <1000 ng/mL, serum TSAT <50%, and serum phosphorus ≥2.5 and ≤8.0 mg/dL at the screening visit. The safety and efficacy of AURYXIA were studied in the 52‐week active‐controlled period (AURYXIA n=292, Active Control n=149), then AURYXIA patients were re‐randomized to either continue AURYXIA treatment or receive placebo during the placebo‐controlled period, weeks 52‐56 (AURYXIA n=96, placebo n=96). The primary endpoint was the change in serum phosphorus from baseline (Week 52) to Week 56 between AURYXIA and placebo. The key secondary endpoint was the change in serum phosphorus from baseline (Week 0) to Week 52 between AURYXIA and Active Control.

CKD=chronic kidney disease; TSAT=transferrin saturation; Active Control=sevelamer carbonate and/or calcium acetate.



AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis


  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children


The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)


  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman


When clinically significant drug interactions are expected, e.g., Ciprofloxacin or Doxycycline, separate timing of administration.


AURYXIA® (ferric citrate) is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information


  1. AURYXIA® [Package Insert]. Cambridge, MA: Akebia Therapeutics, Inc.
  2. Data on File 4, Akebia Therapeutics, Inc.
  3. Data on File 11, Akebia Therapeutics Inc.
  4. Data on File 10, Akebia Therapeutics Inc.
  5. Data on File 6, Akebia Therapeutics Inc.
  6. Data on File 1, Akebia Therapeutics Inc.
  7. National Kidney Foundation, K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201. doi:10.1053/S0272-6386(03)00905-3
  8. Umanath K, Sika M, Niecestro R, et al; Collaborative Study Group. Rationale and study design of a three period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int. 2013;17(1):67-74. doi:10.1111/j.1542-4758.2012.00711.x